nu image medical semaglutide TIRZEPATIDE Semaglutide NYC Weight Loss Program

After 4 to 6 weeks of data, clear patterns emerge

Persistent insomnia may indicate an unrelated sleep disorder, a nutritional deficiency, or a need for protocol adjustments

Here's the realistic timeline: Phase 3 trials (AMAZE program): - AMAZE 1 (obesity) started February 2026, enrolling ~1,150 participants - Primary completion estimated: June 2029 - Phase 3 in T2D also being planned following the ADA 2026 data US FDA approval (projected): Q4 2030 at the earliest (GlobalData estimate) EU EMA approval (projected): Q1 2031 at the earliest Bulgaria and Eastern Europe: Typically 612 months after EMA approval for market access, depending on national reimbursement negotiations

mainly because we have not known how to treat it with a great deal of success

The participants who received the 7.2mg dose lost an average of nearly 21% of their body weight compared with 17.5% for those on the standard dose